Literature DB >> 18155743

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

S Phogat1, K Svehla, M Tang, A Spadaccini, J Muller, J Mascola, I Berkower, R Wyatt.   

Abstract

Vaccine immunogens derived from the envelope glycoproteins of the human immunodeficiency virus type 1 (HIV-1) that elicit broad neutralizing antibodies remain an elusive goal. The highly conserved 30 amino-acid membrane proximal external region (MPER) of HIV gp41 contains the hydrophobic epitopes for two rare HIV-1 broad cross-reactive neutralizing antibodies, 2F5 and 4E10. Both these antibodies possess relatively hydrophobic HCDR3 loops and demonstrate enhanced binding to their epitopes in the context of the native gp160 precursor envelope glycoprotein by the intimate juxtaposition of a lipid membrane. The hepatitis B surface antigen (HBsAg) S1 protein forms nanoparticles that can be utilized both as an immunogenic array of the MPER and to provide the lipid environment needed for enhanced 2F5 and 4E10 binding. We show that recombinant HBsAg particles with MPER (HBsAg-MPER) appended at the C-terminus of the S1 protein are recognized by 2F5 and 4E10 with high affinity compared to positioning the MPER at the N-terminus or the extracellular loop (ECL) of S1. Addition of C-terminal hydrophobic residues derived from the HIV-1 Env transmembrane region further enhances recognition of the MPER by both 2F5 and 4E10. Delipidation of the HBsAg-MPER particles decreases 2F5 and 4E10 binding and subsequent reconstitution with synthetic lipids restores optimal binding. Inoculation of the particles into small animals raised cross-reactive antibodies that recognize both the MPER and HIV-1 gp160 envelope glycoproteins expressed on the cell surface; however, no neutralizing activity could be detected. Prime:Boost immunization of the HBsAg-MPER particles in sequence with HIV envelope glycoprotein proteoliposomes (Env-PLs) did not raise neutralizing antibodies that could be mapped to the MPER region. However, the Env-PLs did raise anti-Env antibodies that had the ability to neutralize selected HIV-1 isolates. The first generation HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155743      PMCID: PMC2706122          DOI: 10.1016/j.virol.2007.11.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

Review 1.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

Review 2.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

3.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

Authors:  Darron R Brown; Kenneth H Fife; Cosette M Wheeler; Laura A Koutsky; Lisa M Lupinacci; Radha Railkar; Gretchen Suhr; Eliav Barr; Anthony Dicello; Weili Li; Judith F Smith; Amha Tadesse; Kathrin U Jansen
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

4.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.

Authors:  Kenneth H Fife; Cosette M Wheeler; Laura A Koutsky; Eliav Barr; Darron R Brown; Melissa A Schiff; Nancy B Kiviat; Kathrin U Jansen; Harriet Barber; Judith F Smith; Amha Tadesse; Katherine Giacoletti; Paula R Smith; Gretchen Suhr; Daniel A Johnson
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

5.  Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen.

Authors:  G A Cabral; F Marciano-Cabral; G A Funk; Y Sanchez; F B Hollinger; J L Melnick; G R Dreesman
Journal:  J Gen Virol       Date:  1978-02       Impact factor: 3.891

6.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

Review 8.  Prevention of cervical cancer through papillomavirus vaccination.

Authors:  Ian H Frazer
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

9.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Human hepatitis B vaccine from recombinant yeast.

Authors:  W J McAleer; E B Buynak; R Z Maigetter; D E Wampler; W J Miller; M R Hilleman
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

View more
  31 in total

1.  Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.

Authors:  Konstantin Virnik; Yisheng Ni; Ira Berkower
Journal:  Vaccine       Date:  2012-07-06       Impact factor: 3.641

2.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

Review 3.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

4.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

5.  Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer.

Authors:  Patrick N Reardon; Harvey Sage; S Moses Dennison; Jeffrey W Martin; Bruce R Donald; S Munir Alam; Barton F Haynes; Leonard D Spicer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

6.  Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Authors:  Yougang Zhai; Zhenyu Zhong; Mohammadreza Zariffard; Gregory T Spear; Liang Qiao
Journal:  Vaccine       Date:  2013-09-19       Impact factor: 3.641

7.  Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Authors:  Robyn L Stanfield; Jean-Philippe Julien; Robert Pejchal; Johannes S Gach; Michael B Zwick; Ian A Wilson
Journal:  J Mol Biol       Date:  2011-10-15       Impact factor: 5.469

8.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1.

Authors:  Audray K Harris; Alberto Bartesaghi; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.